Comparative analysis of formulation buffers and storage temperatures on stability of a novel, recombinant multi-epitope peptide vaccine against COVID-19
Keywords:
stability studies, multi-epitope vaccine, formulation, COVID-19, AdjuvantsAbstract
Background: Formulation of therapeutic proteins is of utmost importance for their stability and biological activity. Protein-based vaccines also require optimal formulation for long term storage, transport and usage. Various analytical studies are performed to evaluate the stability of vaccines over a time period at different storage temperatures.
Objectives: The present study provides a comparative analysis of the stability of a novel multi-epitope COVID-19 vaccine in three different formulation buffers and two different storage temperatures.
Methods: Three different formulation buffers were prepared by addition of different adjuvants (FB01, FB02 and FB03). According to the International Conference on Harmonization (ICH- Q5C) guidelines, real-time and accelerated stability studies were carried out to determine the stability of the novel vaccine candidate at two storage temperatures – +2–8 ºC (real-time, up to 6 months) and +25 ºC (accelerated, up to 1 month).
Results: The stability assessment showed that the recombinant multi-epitope peptide vaccine was more stable at +2–8 ºC storage temperature in all three buffers tested as compared to when stored at +25 ºC.
Conclusion: The study reports that formulation buffer, FB01, is the most preferred buffer for maintaining the stability of the peptide vaccine at +2–8 ºC for 6 months.
Downloads
Metrics
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
